
Martin O Savage

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1390301/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1526-1540.	1.8	2,131
2	Intrauterine Growth Retardation and Postnatal Growth Failure Associated with Deletion of the Insulin-Like Growth Factor I Gene. New England Journal of Medicine, 1996, 335, 1363-1367.	13.9	1,002
3	Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2807-2831.	1.8	899
4	Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4210-4217.	1.8	571
5	Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clinical Endocrinology, 1993, 38, 73-78.	1.2	260
6	Idiopathic short stature: Definition, epidemiology, and diagnostic evaluation. Growth Hormone and IGF Research, 2008, 18, 89-110.	0.5	197
7	Clinical Features Affecting Final Adult Height in Patients With Pediatric-Onset Crohn's Disease. Pediatrics, 2006, 118, 124-129.	1.0	180
8	Evidence for a Continuum of Genetic, Phenotypic, and Biochemical Abnormalities in Children with Growth Hormone Insensitivity. Endocrine Reviews, 2011, 32, 472-497.	8.9	171
9	Clinical features and endocrine status in patients with growth hormone insensitivity (Laron) Tj ETQq1 1 0.784314	t rg₿T /Ov	erlock 10 Tf
10	Clinical features and endocrine status in patients with growth hormone insensitivity (Laron) Tj ETQq0 0 0 rgBT /C	verlock 10 1.8) Tf 50 382 T 149
11	Phenotype: Genotype Relationships in Growth Hormone Insensitivity Syndrome1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3529-3535.	1.8	137
12	Defects in growth hormone receptor signaling. Trends in Endocrinology and Metabolism, 2007, 18, 134-141.	3.1	134
13	Relationship between Insulin, Insulin-Like Growth Factor I, and Dehydroepiandrosterone Sulfate Concentrations During Childhood, Puberty, and Adult Life*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 932-937.	1.8	132
14	Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends in Endocrinology and Metabolism, 2007, 18, 167-174.	3.1	120
15	Growth in Crohn's disease. Acta Paediatrica, International Journal of Paediatrics, 1999, 88, 89-92.	0.7	117
16	A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1686-1690.	1.8	115
17	Improvement of diagnostic criteria in growth hormone insensitivity syndrome: solutions and pitfalls. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 117-124.	0.7	112

18Insulinâ€like growth factor I gene deletion causing intrauterine growth retardation and severe short
stature. Acta Paediatrica, International Journal of Paediatrics, 1997, 86, 39-45.0.7112

#	Article	IF	CITATIONS
19	Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13260-13265.	3.3	111
20	Pseudoexon Activation as a Novel Mechanism for Disease Resulting in Atypical Growth-Hormone Insensitivity. American Journal of Human Genetics, 2001, 69, 641-646.	2.6	110
21	Cushing's Disease in Children and Adolescents: 20 Years of Experience in a Single Neurosurgical Center. Neurosurgery, 2005, 57, 281-285.	0.6	103
22	Expanding the Spectrum of Mutations in GH1 and GHRHR: Genetic Screening in a Large Cohort of Patients with Congenital Isolated Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3191-3199.	1.8	103
23	The Effect of Cessation of Growth Hormone (GH) Therapy on Bone Mineral Accretion in GH-Deficient Adolescents at the Completion of Linear Growth. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1658-1663.	1.8	101
24	Effects of Insulin-Like Growth Factor I (IGF-I) Therapy on Body Composition and Insulin Resistance in IGF-I Gene Deletion. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1407-1411.	1.8	98
25	Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clinical Endocrinology, 1995, 43, 19-28.	1.2	97
26	GONADAL NEOPLASIA AND ABNORMAL SEXUAL DIFFERENTIATION. Clinical Endocrinology, 1990, 32, 519-534.	1.2	93
27	Insulin-Like Growth Factor I Improves Height in Growth Hormone Insensitivity: Two Years' Results. Hormone Research, 1995, 44, 253-264.	1.8	93
28	Comparisons in the epidemiology, diagnostic features and cure rate by transsphenoidal surgery between paediatric and adult-onset Cushing's disease. European Journal of Endocrinology, 2011, 164, 667-674.	1.9	93
29	Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet, The, 1997, 350, 1199-1204.	6.3	92
30	Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clinical Endocrinology, 1998, 49, 483-489.	1.2	92
31	Long-Term Treatment of Growth Hormone Insensitivity Syndrome with IGF-I. Hormone Research in Paediatrics, 1999, 51, 128-134.	0.8	92
32	Classification of growth hormone insensitivity syndrome. Journal of Pediatrics, 1993, 122, 241.	0.9	91
33	Clinical and Endocrine Responses to Pituitary Radiotherapy in Pediatric Cushing's Disease: An Effective Second-Line Treatment. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 34-37.	1.8	89
34	IGF1 molecular anomalies demonstrate its critical role in fetal, postnatal growth and brain development. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 181-190.	2.2	89
35	The growth hormone–insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocrine Connections, 2018, 7, R212-R222.	0.8	81
36	The continuum of growth hormone–IGFâ€I axis defects causing short stature: diagnostic and therapeutic challenges. Clinical Endocrinology, 2010, 72, 721-728.	1.2	79

#	Article	IF	CITATIONS
37	Relative Contributions of Inferior Petrosal Sinus Sampling and Pituitary Imaging in the Investigation of Children and Adolescents with ACTH-Dependent Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5711-5714.	1.8	78
38	Relationships between Serum IGF-1, IGFBP-2, Interleukin-1Beta and Interleukin-6 in Inflammatory Bowel Disease. Hormone Research in Paediatrics, 2004, 61, 159-164.	0.8	78
39	Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 395-407.	2.9	78
40	Final adult height and body mass index after cure of paediatric Cushing's disease. Clinical Endocrinology, 2005, 62, 466-472.	1.2	76
41	Prepubertal Cushing's Disease Is More Common in Males, But There Is No Increase in Severity at Diagnosis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3818-3820.	1.8	75
42	Linear Growth and Final Height after Treatment for Cushing's Disease in Childhood. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3262-3265.	1.8	71
43	Idiopathic short stature: Management and growth hormone treatment. Growth Hormone and IGF Research, 2008, 18, 111-135.	0.5	69
44	The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2291-2297.	1.8	67
45	Effects of Recombinant Human Insulin-Like Growth Factor I (IGF-I) Therapy on the Growth Hormone-IGF System of a Patient with a Partial IGF-I Gene Deletion. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1611-1616.	1.8	67
46	Noonan's Syndrome: Abnormalities of the Growth Hormone/IGF-I Axis and the Response to Treatment with Human Biosynthetic Growth Hormone. Acta Paediatrica, International Journal of Paediatrics, 1991, 80, 446-450.	0.7	65
47	Growth Hormone (GH) Insensitivity Syndrome due to a GH Receptor Truncated after Box1, Resulting in Isolated Failure of STAT 5 Signal Transduction. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1259-1266.	1.8	65
48	Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. European Journal of Endocrinology, 2005, 152, 825-833.	1.9	65
49	Identification and management of poor response to growthâ€promoting therapy in children with short stature. Clinical Endocrinology, 2012, 77, 169-181.	1.2	59
50	Growth Hormone Therapy and Growth in Children with Noonan's Syndrome: Results of 3 Years' Follow-Up*. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1953-1956.	1.8	58
51	Efficient Short-Term Control of Hypercortisolaemia by Low-Dose Etomidate in Severe Paediatric Cushing's Disease. Hormone Research in Paediatrics, 2005, 64, 140-143.	0.8	58
52	Growth hormone insensitivity: a proposed revised classification. Acta Paediatrica, International Journal of Paediatrics, 1999, 88, 147-147.	0.7	55
53	The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism Journal of Clinical Endocrinology and Metabolism, 1992, 74, 56-63.	1.8	52
54	Androgen secreting adrenocortical tumours. Archives of Disease in Childhood, 1999, 80, 46-50.	1.0	51

#	Article	IF	CITATIONS
55	Cushing's Disease in Childhood: Presentation, Investigation, Treatment and Long-Term Outcome. Hormone Research in Paediatrics, 2001, 55, 24-30.	0.8	51
56	An Intronic Growth Hormone Receptor Mutation Causing Activation of a Pseudoexon Is Associated with a Broad Spectrum of Growth Hormone Insensitivity Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 655-659.	1.8	51
57	Clinical and Endocrine Characteristics in Atypical and Classical Growth Hormone Insensitivity Syndrome. Hormone Research in Paediatrics, 2001, 55, 125-130.	0.8	50
58	Growth Hormone Insensitivity and Severe Short Stature in Siblings: A Novel Mutation at the Exon 13-Intron 13 Junction of the <i>STAT5b</i> Gene. Hormone Research in Paediatrics, 2007, 68, 218-224.	0.8	49
59	Abnormal puberty in paediatric Cushing's disease: relationship with adrenal androgen, sex hormone binding globulin and gonadotrophin concentrations. Clinical Endocrinology, 2007, 66, 838-843.	1.2	48
60	Clinical features, diagnosis, treatment and molecular studies in paediatric Cushing's syndrome due to primary nodular adrenocortical hyperplasia. Clinical Endocrinology, 2004, 61, 553-559.	1.2	46
61	Standard and low-dose IGF-I generation tests and spontaneous growth hormone secretion in children with idiopathic short stature. Clinical Endocrinology, 2004, 60, 163-168.	1.2	46
62	Pharmacokinetic Studies of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I)/rhIGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1246-1253.	1.8	45
63	Work-up and management of paediatric Cushing's syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 346-351.	1.2	44
64	Delayed puberty and response to testosterone in a rat model of colitis. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 281, R1483-R1491.	0.9	43
65	The GH–ICF-I axis in children with idiopathic short stature. Trends in Endocrinology and Metabolism, 2002, 13, 325-330.	3.1	40
66	MANAGEMENT OF ENDOCRINE DISEASE: Paediatric Cushing's disease. European Journal of Endocrinology, 2015, 173, R35-R45.	1.9	40
67	Changes in serum IGFâ€I and IGFBPâ€3 concen_trations during the IGFâ€I generation test performed prospectively in children with short stature. Clinical Endocrinology, 1998, 48, 719-724.	1.2	39
68	Successful treatment of childhood-onset Cushing's disease is associated with persistent reduction in growth hormone secretion. Clinical Endocrinology, 2004, 60, 169-174.	1.2	38
69	Endonasal endoscopic transsphenoidal pituitary surgery: early experience and outcome in paediatric <scp>C</scp> ushing's disease. Clinical Endocrinology, 2014, 80, 270-276.	1.2	38
70	Long-term anterior pituitary function in patients with paediatric Cushing's disease treated with pituitary radiotherapy. European Journal of Endocrinology, 2007, 156, 477-482.	1.9	37
71	Insulin-Like Growth Factors, Nutrition and Growth. World Review of Nutrition and Dietetics, 2013, 106, 52-59.	0.1	37
72	Effects of Insulin-Like Growth Factor I (IGF-I) Therapy on Body Composition and Insulin Resistance in IGE-I Gene Deletion, Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1407-1411	1.8	37

#	Article	IF	CITATIONS
73	Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease. Journal of Endocrinological Investigation, 2005, 28, 231-235.	1.8	36
74	Laron syndrome: typical and atypical forms. Bailliere's Clinical Endocrinology and Metabolism, 1996, 10, 371-387.	1.0	35
75	Early Detection, Referral, Investigation, and Diagnosis of Children with Growth Disorders. Hormone Research in Paediatrics, 2016, 85, 325-332.	0.8	35
76	Pediatric Cushing's syndrome: clinical features, diagnosis, and treatment. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 1261-1271.	1.3	34
77	Linear growth and body mass index in pediatric patients with Cushing's disease or simple obesity. Journal of Endocrinological Investigation, 2006, 29, 885-887.	1.8	33
78	Growth Hormone Insensitivity: Pathophysiology, Diagnosis, Clinical Variation and Future Perspectives. Hormone Research in Paediatrics, 2001, 55, 32-35.	0.8	32
79	Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action. Endocrine Reviews, 2019, 40, 476-505.	8.9	32
80	The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome). Clinical Endocrinology, 1993, 39, 119-122.	1.2	30
81	Abnormal Growth in Noonan Syndrome: Genetic and Endocrine Features and Optimal Treatment. Hormone Research, 2008, 70, 129-136.	1.8	30
82	Whole-exome sequencing gives additional benefits compared to candidate gene sequencing in the molecular diagnosis of children with growth hormone or IGF-1 insensitivity. European Journal of Endocrinology, 2017, 177, 485-501.	1.9	30
83	Growth response to rhIGF-I 80â€∫μg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype. Clinical Endocrinology, 1999, 51, 787-792.	1.2	29
84	Therapeutic applications of the insulin-like growth factors. Growth Hormone and IGF Research, 2004, 14, 301-308.	0.5	29
85	A 36 residues insertion in the dimerization domain of the growth hormone receptor results in defective trafficking rather than impaired signaling. Journal of Endocrinology, 2006, 188, 251-261.	1.2	29
86	Genetic Defects in the Growth Hormone?IGF-I Axis Causing Growth Hormone Insensitivity and Impaired Linear Growth. Frontiers in Endocrinology, 2011, 2, 95.	1.5	29
87	Genetic characterisation of a cohort of children clinically labelled as GH or IGF1 insensitive: diagnostic value of serum IGF1 and height at presentation. European Journal of Endocrinology, 2015, 172, 151-161.	1.9	29
88	Long-term outcomes of children treated for Cushing's disease: a single center experience. Pituitary, 2016, 19, 612-624.	1.6	29
89	The â€~dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1. Clinical Endocrinology, 1995, 43, 567-574.	1.2	28
90	Diagnosis, management and therapeutic outcome in prepubertal Cushing's disease. European Journal of Endocrinology, 2010, 162, 603-609.	1.9	28

#	Article	IF	CITATIONS
91	Use of Intravenous Etomidate to Control Acute Psychosis Induced by the Hypercortisolaemia in Severe Paediatric Cushing's Disease. Hormone Research in Paediatrics, 2011, 75, 441-446.	0.8	28
92	Cushing's disease in childhood. Trends in Endocrinology and Metabolism, 1996, 7, 213-216.	3.1	27
93	The Discriminatory Value of the Low-Dose Dexamethasone Suppression Test in the Investigation of Paediatric Cushing's Syndrome. Hormone Research in Paediatrics, 2006, 65, 159-162.	0.8	26
94	Novel Dominant-Negative GH Receptor Mutations Expands the Spectrum of GHI and IGF-I Deficiency. Journal of the Endocrine Society, 2017, 1, 345-358.	0.1	26
95	Pediatric Cushing′s disease: Management Issues. Indian Journal of Endocrinology and Metabolism, 2012, 16, 171.	0.2	26
96	Clinical and endocrine features and long-term outcome of Graves' disease in early childhood. Journal of Endocrinological Investigation, 2007, 30, 388-392.	1.8	25
97	Growth in Disorders of Adrenal Hyperfunction. Hormone Research in Paediatrics, 2002, 58, 39-43.	0.8	24
98	IGFs and IGFBPs in GH Insensitivity. , 2005, 9, 100-106.		24
99	Idiopathic short stature: will genetics influence the choice between GH and IGF-I therapy?. European Journal of Endocrinology, 2007, 157, S33-S37.	1.9	24
100	Magnetic resonance imaging of adrenocortical adenomas in childhood: Correlation with computed tomography and ultrasound. Pediatric Radiology, 1996, 26, 794-799.	1.1	23
101	Transitional care of GH deficiency: when to stop GH therapy. European Journal of Endocrinology, 2004, 151 Suppl 1, S61-S65.	1.9	23
102	Diagnosis and treatment of pediatric Cushing's disease. Pituitary, 2007, 10, 365-371.	1.6	23
103	Acid-Labile Subunit Deficiency and Growth Failure: Description of Two Novel Cases. Hormone Research in Paediatrics, 2010, 73, 328-334.	0.8	23
104	Paediatric Cushing's disease: Epidemiology, pathogenesis, clinical management and outcome. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 817-835.	2.6	23
105	Effects of recombinant insulin-like growth factor I on craniofacial morphology in growth hormone insensitivity. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 140-141.	0.7	22
106	Acceleration of pubertal development following pituitary radiotherapy for Cushing's disease. Clinical Oncology, 1993, 5, 393-394.	0.6	21
107	Clinical presentation, growth, and pubertal development in Addison's disease Archives of Disease in Childhood, 1985, 60, 925-928.	1.0	20
108	Factors Influencing Skeletal Maturation at Diagnosis of Paediatric Cushing's Disease. Hormone Research in Paediatrics, 2007, 68, 231-235.	0.8	20

#	Article	IF	CITATIONS
109	Abnormal linear growth in paediatric adrenal diseases: Pathogenesis, prevalence and management. Clinical Endocrinology, 2020, 92, 98-108.	1.2	20
110	The variability of responses to growth hormone therapy in children with short stature. Indian Journal of Endocrinology and Metabolism, 2012, 16, 178.	0.2	20
111	Growth patterns after surgery for virilising adrenocortical adenoma Archives of Disease in Childhood, 1992, 67, 234-236.	1.0	19
112	Diagnostic and Therapeutic Advances in Growth Hormone Insensitivity. Endocrinology and Metabolism Clinics of North America, 2005, 34, 581-595.	1.2	19
113	Analysis of the intracellular signalling domain of the human growth hormone receptor in children with idiopathic short stature. Clinical Endocrinology, 2000, 52, 463-469.	1.2	18
114	Phenotypes, Investigation and Treatment of Primary IGF-1 Deficiency. Endocrine Development, 2013, 24, 138-149.	1.3	18
115	Phenotypic spectrum and responses to recombinant human IGF1 (rhIGF1) therapy in patients with homozygous intronic pseudoexon growth hormone receptor mutation. European Journal of Endocrinology, 2018, 178, 481-489.	1.9	17
116	Growth failure: â€~idiopathic' only after a detailed diagnostic evaluation. Endocrine Connections, 2021, 10, R125-R138.	0.8	17
117	Defects of the growth hormonereceptor and their clinical implications. Growth Hormone and IGF Research, 1999, 9, 57-61.	0.5	16
118	Identification and characterisation of a novel GHR defect disrupting the polypyrimidine tract and resulting in GH insensitivity. European Journal of Endocrinology, 2010, 162, 37-42.	1.9	16
119	Achieving Optimal Short- and Long-term Responses to Paediatric Growth Hormone Therapy. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2019, 11, 329-340.	0.4	16
120	Insulin and Growth Factors Adaptation to Normal Puberty. Hormone Research, 1992, 37, 70-73.	1.8	15
121	Spontaneous growth hormone secretory characteristics in children with partial growth hormone insensitivity. Clinical Endocrinology, 2002, 57, 357-361.	1.2	15
122	Digital Health for Supporting Precision Medicine in Pediatric Endocrine Disorders: Opportunities for Improved Patient Care. Frontiers in Pediatrics, 2021, 9, 715705.	0.9	15
123	Investigation for Paediatric Cushing's Syndrome Using Twenty-Four-Hour Urinary Free Cortisol Determination. Hormone Research in Paediatrics, 2016, 86, 21-26.	0.8	14
124	Advances in the Management of Paediatric Cushing's Disease. Hormone Research in Paediatrics, 2008, 69, 327-333.	0.8	13
125	Heterogeneity of the growth phenotype and birth size in acid-labile subunit (ALS) deficiency. Journal of Endocrinological Investigation, 2015, 38, 407-412.	1.8	12
126	Genetic Characterization of Short Stature Patients With Overlapping Features of Growth Hormone Insensitivity Syndromes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4716-e4733.	1.8	11

#	Article	IF	CITATIONS
127	Digital technologies to improve the precision of paediatric growth disorder diagnosis and management. Growth Hormone and IGF Research, 2021, 59, 101408.	0.5	11
128	The role of corticotrophin-releasing hormone in the diagnosis of Cushing's syndrome. European Journal of Endocrinology, 2006, 155, S93-S98.	1.9	10
129	When and how to transfer patients from paediatric to adult endocrinologists: experience from St Bartholomew's Hospital, London. Acta Paediatrica, International Journal of Paediatrics, 1997, 86, 127-128.	0.7	9
130	Clinical Spectrum of the Syndrome of Growth Hormone Insensitivity. Acta Paediatrica, International Journal of Paediatrics, 1991, 80, 87-90.	0.7	8
131	The investigation of growth hormone insensitivity. Clinical Endocrinology, 1996, 45, 257-260.	1.2	8
132	Diagnosis and management of growth disorders in Gulf Cooperation Council (GCC) countries: Current procedures and key recommendations for best practice. International Journal of Pediatrics and Adolescent Medicine, 2016, 3, 91-102.	0.5	8
133	Should idiopathic short stature be treated with growth hormone?. Nature Reviews Endocrinology, 2009, 5, 148-149.	4.3	7
134	Growth hormone insensitivity syndromes. Acta Paediatrica, International Journal of Paediatrics, 1995, 84, 87-90.	0.7	6
135	Luteinizing hormone secreting adrenal tumour as a cause of precocious puberty. Clinical Endocrinology, 1998, 48, 367-372.	1.2	6
136	Normal final height and apparent cure after pituitary irradiation for Cushing's disease in childhood: long-term follow-up of anterior pituitary function. Clinical Endocrinology, 1998, 48, 663-667.	1.2	6
137	Cushing's syndrome in infancy due to ectopic ACTH secretion by a sacro-coccygeal teratoma. Journal of Pediatric Endocrinology and Metabolism, 2017, 30, 475-478.	0.4	6
138	The value of whole exome sequencing for genetic diagnosis in a patient with Bloom syndrome. Journal of Endocrinological Investigation, 2021, 44, 1331-1334.	1.8	6
139	Managing Paediatric Growth Disorders: Integrating Technology Into a Personalised Approach. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2020, 12, 225-232.	0.4	6
140	Adherence to r-hGH Therapy in Pediatric Growth Hormone Deficiency: Current Perspectives on How Patient-Generated Data Will Transform r-hGH Treatment Towards Integrated Care. Patient Preference and Adherence, 0, Volume 16, 1663-1671.	0.8	6
141	Novel Growth Hormone Receptor Mutation in a Chinese Patient with Laron Syndrome. Journal of Pediatric Endocrinology and Metabolism, 2005, 18, 209-13.	0.4	5
142	Global Inequalities in Paediatric Endocrine Practice: Statement of Minimal Acceptable Care. Hormone Research in Paediatrics, 2006, 65, 111-113.	0.8	5
143	Insulin-like growth factors and their binding proteins in patients with growth hormone receptor deficiency: suggestions for new diagnostic criteria. The Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Acta Paediatrica, International Journal of Paediatrics. Supplement, 1992. 383. 125-6.	1.0	5
144	GH Resistance Is a Component of Idiopathic Short Stature: Implications for rhGH Therapy. Frontiers in Endocrinology, 2021, 12, 781044.	1.5	5

#	Article	IF	CITATIONS
145	Phenotypic Aspects of Growth Hormone- and IGF-I-Resistant Syndromes. Endocrine Development, 2009, 14, 143-150.	1.3	4
146	Diagnosis and Treatment of Cushing's Disease in Children. Endocrine Development, 2009, 17, 134-145.	1.3	4
147	Growthâ€promoting Hormone Therapy in Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, S135-6.	0.9	4
148	Fundamental principles of clinical and biochemical evaluation underlie the diagnosis and therapy of Cushing's syndrome. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 1029-1031.	0.4	4
149	The continuum between GH deficiency and GH insensitivity in children. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 91-99.	2.6	4
150	Growth Hormone Receptor <i>(GHR)</i> 6Ω Pseudoexon Activation: A Novel Cause of Severe Growth Hormone Insensitivity. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e401-e416.	1.8	4
151	GHR gene transcript heterogeneity may explain phenotypic variability in GHR pseudoexon (6ΰ) patients. Endocrine Connections, 2020, 9, 211-222.	0.8	4
152	Recombinant IGF-I therapy in insulin-dependent diabetes mellitus. Diabetes and Metabolism, 1996, 22, 257-60.	1.4	4
153	Final Height in Patients with Idiopathic Short Stature and High Growth Hormone Responses to Stimulation Tests. Hormone Research in Paediatrics, 2007, 67, 224-230.	0.8	2
154	Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistance. Journal of Endocrinological Investigation, 2007, 30, 439-441.	1.8	2
155	Pathophysiology, assessment and management of the child with growth hormone resistance. Pediatric Endocrinology Reviews, 2010, 7, 347-56.	1.2	2
156	Patients' Perception of the Use of the EasyPodâ,,¢ Growth Hormone Injector Device and Impact on Injection Adherence: A Multi-Center Regional Study. Frontiers in Pediatrics, 2022, 10, 839278.	0.9	2
157	The combined pituitary function test is not indicated in the routine investigation of short stature. Clinical Endocrinology, 2000, 52, 679-679.	1.2	1
158	Diagnosis of pediatric Cushing's syndrome—which test is best?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 76-77.	2.9	1
159	Abnormal growth in noonan syndrome: the challenge of optimal therapy. Pediatric Endocrinology Reviews, 2009, 6 Suppl 4, 523-8.	1.2	1
160	Management of Chronic Systemic Diseases. Hormone Research in Paediatrics, 2007, 68, 112-112.	0.8	0
161	Growth and body composition at diagnosis and postcure in children with Cushing's syndrome. Pediatric Health, 2009, 3, 13-18.	0.3	0
162	Pediatric Cushing Disease. , 2019, , 444-453.		0

162 Pediatric Cushing Disease. , 2019, , 444-453.

#	Article	IF	CITATIONS
163	Adrenal disorders. , 2007, , .		0
164	Special Aspects of Cushing's Syndrome: Childhood. , 2010, , 273-282.		0
165	Diagnosis and Treatment of Pediatric Cushing's Disease. Growth Hormone, 2011, , 197-210.	0.2	0
166	Le continuum des résistances à l'hormone de croissance : du retard statural idiopathique au syndrome de Laron. , 2012, , 187-201.		0
167	Growth Hormone Insensitivity Syndrome (GHIS): Clinical Presentation and Effects of Treatment with Recombinant Human Insulin-like Growth Factor I (rhIGF-I) European Experience. Clinical Pediatric Endocrinology, 1994, 3, 115-121.	0.4	0
168	The Clinical and Endocrine Spectrum of Growth Hormone Insensitivity Syndrome (GHIS). Clinical Pediatric Endocrinology, 1994, 3, 245-245.	0.4	0
169	Growth Hormone Insensitivity. , 2018, , 81-93.		0
170	SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease. Journal of the Endocrine Society, 2019, 3, .	0.1	0
171	Growth hormone insensitivity. , 2000, 71, 111-7.		0
172	Phenotypic variability in growth hormone insensitivity. Journal of Pediatric Endocrinology and Metabolism, 2002, 15 Suppl 5, 1449-50.	0.4	0
173	The Changing Face of Paediatric Human Growth Hormone Therapy. Endocrines, 2022, 3, 419-427.	0.4	0
174	Evaluating the sensitivity and specificity of the UK and Dutch growth referral criteria in predicting the diagnosis of pathological short stature. BMJ Paediatrics Open, 2022, 6, e001385.	0.6	0